Cantor Fitzgerald Comments on Cabaletta Bio FY2025 Earnings

Cabaletta Bio, Inc. (NASDAQ:CABA) – Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Cabaletta Bio in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer anticipates that the company will post earnings per share of ($2.19) for the year. The consensus estimate for Cabaletta Bio’s current full-year earnings is ($2.34) per share.

A number of other equities analysts have also recently issued reports on CABA. Wells Fargo & Company cut Cabaletta Bio from an “overweight” rating to an “equal weight” rating and lowered their target price for the stock from $12.00 to $6.00 in a report on Thursday, December 19th. UBS Group started coverage on Cabaletta Bio in a research report on Thursday, October 10th. They issued a “buy” rating and a $10.00 target price on the stock. Evercore ISI downgraded shares of Cabaletta Bio from an “outperform” rating to an “inline” rating and lowered their price objective for the company from $15.00 to $6.00 in a report on Friday, December 20th. William Blair reaffirmed an “outperform” rating on shares of Cabaletta Bio in a research report on Monday, November 18th. Finally, HC Wainwright reissued a “buy” rating and set a $25.00 price target on shares of Cabaletta Bio in a research report on Friday, January 17th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Cabaletta Bio currently has a consensus rating of “Buy” and a consensus target price of $24.38.

Cabaletta Bio Stock Down 2.3 %

Shares of CABA stock opened at $2.54 on Thursday. Cabaletta Bio has a 12-month low of $1.76 and a 12-month high of $26.35. The firm has a fifty day moving average of $2.65 and a 200-day moving average of $4.30. The company has a market capitalization of $124.16 million, a price-to-earnings ratio of -1.18 and a beta of 2.46.

Hedge Funds Weigh In On Cabaletta Bio

A number of hedge funds have recently made changes to their positions in CABA. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Cabaletta Bio in the 3rd quarter valued at $32,000. Point72 DIFC Ltd acquired a new position in Cabaletta Bio in the third quarter valued at $33,000. China Universal Asset Management Co. Ltd. boosted its position in Cabaletta Bio by 65.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,395 shares of the company’s stock valued at $44,000 after acquiring an additional 3,724 shares during the last quarter. Intech Investment Management LLC acquired a new stake in Cabaletta Bio during the 3rd quarter worth about $67,000. Finally, Avanza Fonder AB bought a new position in shares of Cabaletta Bio in the 4th quarter worth about $40,000.

About Cabaletta Bio

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.